HKD 7.63
(-1.68%)
Year | Operating Income | Operating Income Growth |
---|---|---|
2023 | 884.96 Million CNY | 23.7% |
2022 | 715.4 Million CNY | 8.37% |
2021 | 660.18 Million CNY | 20.01% |
2020 | 550.12 Million CNY | 10.83% |
2019 | 496.37 Million CNY | -24.25% |
2018 | 655.32 Million CNY | 22.85% |
2017 | 533.43 Million CNY | 33.88% |
2016 | 398.45 Million CNY | 35.56% |
2015 | 293.92 Million CNY | 24.83% |
2014 | 235.46 Million CNY | 14.39% |
2013 | 205.83 Million CNY | 13.7% |
2012 | 181.02 Million CNY | 0.0% |
Year | Operating Income | Operating Income Growth |
---|---|---|
2024 Q2 | 447.33 Million CNY | 0.0% |
2023 FY | 884.96 Million CNY | 23.7% |
2023 Q4 | 500.15 Million CNY | 0.0% |
2023 Q2 | 359.96 Million CNY | 0.0% |
2022 Q2 | 297.46 Million CNY | 0.0% |
2022 FY | 715.4 Million CNY | 8.37% |
2022 Q4 | 417.94 Million CNY | 0.0% |
2021 Q2 | 286.89 Million CNY | 0.0% |
2021 FY | 660.18 Million CNY | 20.01% |
2021 Q4 | 373.28 Million CNY | 0.0% |
2020 Q4 | 303.41 Million CNY | 0.0% |
2020 FY | 550.12 Million CNY | 10.83% |
2020 Q2 | 246.71 Million CNY | 0.0% |
2019 Q4 | 171.5 Million CNY | 0.0% |
2019 FY | 496.37 Million CNY | -24.25% |
2019 Q2 | 324.87 Million CNY | 0.0% |
2018 Q4 | 347.3 Million CNY | 0.0% |
2018 Q2 | 308.02 Million CNY | 0.0% |
2018 FY | 655.32 Million CNY | 22.85% |
2017 Q2 | 264.42 Million CNY | 0.0% |
2017 FY | 533.43 Million CNY | 33.88% |
2017 Q4 | 269.01 Million CNY | 0.0% |
2016 Q4 | 224.97 Million CNY | 0.0% |
2016 FY | 398.45 Million CNY | 35.56% |
2016 Q2 | 173.47 Million CNY | 0.0% |
2015 Q2 | 137.38 Million CNY | 0.0% |
2015 FY | 293.92 Million CNY | 24.83% |
2015 Q4 | 156.54 Million CNY | 0.0% |
2014 Q2 | 96.29 Million CNY | 0.0% |
2014 Q4 | 139.16 Million CNY | 0.0% |
2014 FY | 235.46 Million CNY | 14.39% |
2013 Q4 | 125.86 Million CNY | 0.0% |
2013 FY | 205.83 Million CNY | 13.7% |
2013 Q2 | 79.97 Million CNY | 0.0% |
2012 Q3 | 44.76 Million CNY | 0.0% |
2012 Q4 | 52.61 Million CNY | 17.54% |
2012 Q2 | 44.76 Million CNY | 0.0% |
2012 Q1 | 44.76 Million CNY | 0.0% |
2012 FY | 181.02 Million CNY | 0.0% |
2011 Q4 | 44.76 Million CNY | 0.0% |
Name | Operating Income | Operating Income Difference |
---|---|---|
Pak Fah Yeow International Limited | 143.01 Million HKD | -518.806% |
Grand Pharmaceutical Group Limited | 2.66 Billion HKD | 66.773% |
Extrawell Pharmaceutical Holdings Limited | -8.16 Million HKD | 10942.526% |
Wai Yuen Tong Medicine Holdings Limited | 40.88 Million HKD | -2064.792% |
Qianhai Health Holdings Limited | -52.18 Million HKD | 1795.891% |
Lee's Pharmaceutical Holdings Limited | 36.04 Million HKD | -2355.377% |
Essex Bio-Technology Limited | 310.32 Million HKD | -185.17% |
Tongfang Kontafarma Holdings Limited | - HKD | -Infinity% |
PuraPharm Corporation Limited | -66.04 Million HKD | 1439.925% |
SSY Group Limited | 1.63 Billion HKD | 46.002% |
JBM (Healthcare) Limited | 174.2 Million HKD | -408.003% |
Jacobson Pharma Corporation Limited | 333.12 Million HKD | -165.655% |
China Resources Pharmaceutical Group Limited | 12.14 Billion HKD | 92.715% |